68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy

Hamed, Maged Abdel Galil; Basha, Mohammad Abd Alkhalik; Ahmed, Hussien; Obaya, Ahmed A.; Afifi, Amira Hamed Mohamed; Abdelbary, Eman Hassan

doi:10.1016/j.acra.2018.05.020

Cited by 18 publications

(17 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, their cohort included patients not only after primary radical prostatectomy but also after primary radiation therapy, which might influence the detection rate. Others reported only small cohorts of 10-24 patients and found detection rates between 36% and 57.9% (19)(20)(21)(22). In our 68 Ga-PSMA-11 PET/MRI cohort, we observed a considerably higher detection rate of 65% in patients presenting with PSA values between 0.2 and 0.5 ng/mL at the time of the scan.…”

Section: Discussionmentioning

confidence: 38%

Detection Rate and Localization of Prostate Cancer Recurrence Using ⁶⁸Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL

et al. 2019

View full text Add to dashboard Cite

A first analysis of simultaneous 68 Ga-prostate-specific membrane antigen (PSMA)-11 PET/MRI showed some improvement in the detection of recurrent disease at low serum prostate specific antigen (PSA) values below 0.5 ng/mL compared with the already high detection rate of 68 Ga-PSMA-11 PET/CT. We therefore focused on all patients with biochemical recurrence and PSA values no higher than 0.5 ng/mL to assess the detection rate for 68 Ga-PSMA-11 PET/MRI. Methods: We retrospectively analyzed a cohort of 66 consecutive patients who underwent 68 Ga-PSMA-11 PET/MRI for biochemical recurrence with a PSA value no higher than 0.5 ng/mL at our institution. Median PSA level was 0.23 ng/mL (range, 0.03-0.5 ng/mL). Detection of PSMA-positive lesions within the prostate fossa, local and distant lymph nodes, bones, or visceral organs was recorded. In addition, all scans with 68 Ga-PSMA-11 PET/MRI-positive lesions were retrospectively assessed to analyze if lesions were detected inside or outside a standard salvage radiotherapy volume. Results: Overall, in 36 of 66 patients (54.5%) PSMA-positive lesions were detected; in 26 of 40 (65%) patients with a PSA level between 0.2 and 0.5 ng/mL and in 10 of 26 (38.5%) patients with a PSA level less than 0.2 ng/mL. Even at those low PSA values, only 8 of 66 (12.1%) patients had exclusive local recurrence. Lymph nodes were detected in 23 patients and bone metastases in 5 on 68 Ga-PSMA-11 PET/MRI. In 26 of 66 patients (39.4%), PSMA-positive lesions were located outside a standard salvage radiotherapy volume. Conclusion: Our data confirm that 68 Ga-PSMA-11 PET/MRI has a high detection rate for recurrent prostate cancer, even at low PSA levels no higher than 0.5 ng/mL. In addition, we show that 68 Ga-PSMA-11 PET/MRI detected PSMA-positive lesions outside a standard salvage radiotherapy volume in 39.4% of all patients.

show abstract

Section: Discussionmentioning

confidence: 38%

Detection Rate and Localization of Prostate Cancer Recurrence Using ⁶⁸Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Specifically, in the patient selection, we only enrolled the preoperative patients without hormone therapy, however, Perera et al [15] included a result of mixed staging patients including primary staging and secondary staging patients with BCR. With regard to the patients with BCR, several previous articles revealed a high sensitivity of LNMs detection, ranging from 77.9% to 98.8% [38][39][40]. The results above prompted us that 68 Ga-PSMA PET/CT probably had a superior detection rate in the patients with BCR.…”

Section: Discussionmentioning

confidence: 84%

Diagnostic Performance of ⁶⁸Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis

Xu²,

Wang

et al. 2020

World J Mens Health

View full text Add to dashboard Cite

Purpose: To compare the diagnostic efficiency of 68 Gallium labelled prostate-specific membrane antigen positron emission tomography (68 Ga-PSMA PET) and magnetic resonance imaging (MRI) for staging the lymph node metastases (LNMs) in the prostate cancer. Materials and Methods: A broad search of scientific databases including PubMed, EMBASE, Web of Science, Cochrane Database, and Chinese Biomedicine Literature Database (updated prior to November 1st, 2018) was conducted systematically by two reviewers. In this paper, we evaluated the methodological quality of each included article independently and performed a systematic review and meta-analysis to reveal the summary of the diagnostic performance of 68 Ga-PSMA PET and MRI in properly identifying LNMs of intermediate-and/or high-risk prostate cancer. Results: Thirteen eligible articles comprising 1,597 patients were included. For LNMs detection, the pooled sensitivity and specificity of 68 Ga-PSMA PET were 0.65 (95% confidence interval [CI]: 0.49-0.79) and 0.94 (95% CI: 0.88-0.97), respectively, while the corresponding values of MRI were 0.41 (95% CI: 0.26-0.57) and 0.92 (95% CI: 0.86-0.95). The area under the symmetric receiver-operating characteristic (SROC) curve for 68 Ga-PSMA PET and MRI were 0.92 and 0.83, respectively. Conclusions: In intermediate-or high-risk pre-treatment prostate cancer, 68 Ga-PSMA PET had a higher sensitivity and a slightly different specificity in probing the LNMs when comparing with MRI. Moreover, the area under the SROC curve indicated that 68 Ga-PSMA PET was a more effective weapon for predicting the LNMs prior to radical surgery.

show abstract

“…Recently, Hamed et al . presented a prospective study with 106 out of 165 patients presenting with local recurrence and extraprostatic metastases, in which sensitivity, specificity and accuracy of 68 Ga-PSMA was 99.0%, 100% and 98.8%, respectively, compared to histopathology 24 . In 2016, a study was published by Herlemann et al .…”

Section: Discussionmentioning

confidence: 99%

Accuracy of standard clinical 3T prostate MRI for pelvic lymph node staging: Comparison to 68Ga-PSMA PET-CT

Meißner

Janssen

Prasad

et al. 2019

Sci Rep

View full text Add to dashboard Cite

The aim was to assess the performance of prostate 3T MRI for pelvic lymph node (LN) staging in prostate cancer (PCa), in comparison to 68 Gallium-prostate specific membrane antigen PET-CT ( 68 Ga-PSMA PET-CT) as reference standard for LN detection. 130 patients with PCa underwent non-contrast-enhanced multiparametric prostate 3T MRI and 68 Ga-PSMA-PET-CT within 180 days at our institution. Overall, 187 LN metastases (n = 43 patients) detected by 68 Ga-PSMA-PET-CT were characterized by calculating maximum standardized uptake value (SUVmax), area, diameter and anatomical location including iliac, obturator, presacral and inguinal region. MRI achieved an overall sensitivity, specificity, positive and negative predictive value of 81.6% (CI 71.1–88.9%), 98.6% (CI 97.6–99.2%), 73.5% (CI 52.1–87.6%) and 99.5% (CI 98.8–99.8%), respectively. On a region-based analysis, detection rates differed non-significantly (ps > 0.12) in the anatomical regions. On a size-dependent analysis, detection of LN > 10 mm did not differ significantly (ps > 0.09) from LN ≤ 10 mm. In comparison to single T1 sequence evaluation, additional use of the T2 weighted sequences did not improve the overall performance significantly (p > 0.05). 3T prostate MRI represented an accurate tool for the detection of LN compared to 68 Ga-PSMA-PET-CT. Especially for LN metastases smaller than 10 mm, MRI was less accurate compared to 68 Ga-PSMA-PET-CT.

show abstract

68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy

Cited by 18 publications

References 35 publications

Detection Rate and Localization of Prostate Cancer Recurrence Using ⁶⁸Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL

Detection Rate and Localization of Prostate Cancer Recurrence Using ⁶⁸Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL

Diagnostic Performance of ⁶⁸Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis

Accuracy of standard clinical 3T prostate MRI for pelvic lymph node staging: Comparison to 68Ga-PSMA PET-CT

Contact Info

Product

Resources

About

68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy

Cited by 18 publications

References 35 publications

Detection Rate and Localization of Prostate Cancer Recurrence Using 68Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL

Detection Rate and Localization of Prostate Cancer Recurrence Using 68Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL

Diagnostic Performance of 68Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis

Accuracy of standard clinical 3T prostate MRI for pelvic lymph node staging: Comparison to 68Ga-PSMA PET-CT

Contact Info

Product

Resources

About

Detection Rate and Localization of Prostate Cancer Recurrence Using ⁶⁸Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL

Detection Rate and Localization of Prostate Cancer Recurrence Using ⁶⁸Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL

Diagnostic Performance of ⁶⁸Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis